STAR
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
Strides Pharma Science Enters Agreement To Buy, In-License Generic Brands From Sandoz In Africa
March 17 (Reuters) - Strides Pharma Science Ltd SRID.NS:
STRIDES PHARMA SCIENCE LTD - ENTERS AGREEMENT TO BUY AND IN-LICENSE GENERIC BRANDS FROM SANDOZ IN AFRICA
STRIDES PHARMA SCIENCE LTD - INITIAL CONSIDERATION FOR TRANSACTION IS US$ 12 MILLION
STRIDES PHARMA SCIENCE LTD - DEAL EXPECTED TO CLOSE BY END OF Q2 FY27 PENDING REGULATORY APPROVALS
Source text: ID:nBSE8gPcSB
Further company coverage: SRID.NS
March 17 (Reuters) - Strides Pharma Science Ltd SRID.NS:
STRIDES PHARMA SCIENCE LTD - ENTERS AGREEMENT TO BUY AND IN-LICENSE GENERIC BRANDS FROM SANDOZ IN AFRICA
STRIDES PHARMA SCIENCE LTD - INITIAL CONSIDERATION FOR TRANSACTION IS US$ 12 MILLION
STRIDES PHARMA SCIENCE LTD - DEAL EXPECTED TO CLOSE BY END OF Q2 FY27 PENDING REGULATORY APPROVALS
Source text: ID:nBSE8gPcSB
Further company coverage: SRID.NS
Strides Pharma Science Says Unit Gets USFDA EIR Report For Formulations Facility At Chestnut Ridge
Feb 5 (Reuters) - Strides Pharma Science Ltd SRID.NS:
UNIT GETS USFDA EIR REPORT FOR FORMULATIONS FACILITY AT CHESTNUT RIDGE
Further company coverage: SRID.NS
Feb 5 (Reuters) - Strides Pharma Science Ltd SRID.NS:
UNIT GETS USFDA EIR REPORT FOR FORMULATIONS FACILITY AT CHESTNUT RIDGE
Further company coverage: SRID.NS
Strides Pharma Science Ltd Dec-Quarter Consol Net Profit 2.02 Billion Rupees
Jan 30 (Reuters) - Strides Pharma Science Ltd SRID.NS:
STRIDES PHARMA SCIENCE LTD - DEC-QUARTER CONSOL NET PROFIT 2.02 BILLION RUPEES
STRIDES PHARMA SCIENCE LTD DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 11.95 BILLION RUPEES
Further company coverage: SRID.NS
Jan 30 (Reuters) - Strides Pharma Science Ltd SRID.NS:
STRIDES PHARMA SCIENCE LTD - DEC-QUARTER CONSOL NET PROFIT 2.02 BILLION RUPEES
STRIDES PHARMA SCIENCE LTD DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 11.95 BILLION RUPEES
Further company coverage: SRID.NS
Strides Pharma Science Sept-Quarter Consol Net Profit 1.28 Billion Rupees
Oct 31 (Reuters) - Strides Pharma Science Ltd SRID.NS:
SEPT-QUARTER CONSOL NET PROFIT 1.28 BILLION RUPEES
SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 12.21 BILLION RUPEES
Source text: [ID:]
Further company coverage: SRID.NS
Oct 31 (Reuters) - Strides Pharma Science Ltd SRID.NS:
SEPT-QUARTER CONSOL NET PROFIT 1.28 BILLION RUPEES
SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 12.21 BILLION RUPEES
Source text: [ID:]
Further company coverage: SRID.NS
Strides Pharma Science Partners With Kenox To Expand Nasal Spray Portfolio
Strides Pharma Science Says Unit To Divest 100% Stake In Strides CIS
June 16 (Reuters) - Strides Pharma Science Ltd SRID.NS:
UNIT TO DIVEST 100% STAKE IN STRIDES CIS LIMITED
Source text: ID:nBSE8QfTWN
Further company coverage: SRID.NS
June 16 (Reuters) - Strides Pharma Science Ltd SRID.NS:
UNIT TO DIVEST 100% STAKE IN STRIDES CIS LIMITED
Source text: ID:nBSE8QfTWN
Further company coverage: SRID.NS
India's Strides Pharma rises on quarterly profit surge, boosted by US sales
** Shares of Strides Pharma Science SRID.NS rise 2.4% to 709 rupees
** Co's Q4 consolidated net profit jumps nearly five-fold Y/Y to 856.2 mln rupees ($10 mln), revenue rose ~14%
** SRID says it beat its forecast on all key metrics, including revenue, EBITDA
** Adds, growth led by US business growth, up 21.8% Y/Y and new launches
** Stock up ~5.5% YTD, eyes extending rally for a fourth session
($1 = 85.9340 Indian rupees)
(Reporting by Yagnoseni Das in Bengaluru)
** Shares of Strides Pharma Science SRID.NS rise 2.4% to 709 rupees
** Co's Q4 consolidated net profit jumps nearly five-fold Y/Y to 856.2 mln rupees ($10 mln), revenue rose ~14%
** SRID says it beat its forecast on all key metrics, including revenue, EBITDA
** Adds, growth led by US business growth, up 21.8% Y/Y and new launches
** Stock up ~5.5% YTD, eyes extending rally for a fourth session
($1 = 85.9340 Indian rupees)
(Reporting by Yagnoseni Das in Bengaluru)
Strides Pharma Science, Arco Lab Approve Demerger Of Identified Business Of Arco Lab
March 19 (Reuters) - Strides Pharma Science Ltd SRID.NS:
STRIDES PHARMA SCIENCE - CO, ARCO LAB APPROVE DEMERGER OF IDENTIFIED BUSINESS OF ARCO LAB
Source text: ID:nNSEbkyWGB
Further company coverage: SRID.NS
March 19 (Reuters) - Strides Pharma Science Ltd SRID.NS:
STRIDES PHARMA SCIENCE - CO, ARCO LAB APPROVE DEMERGER OF IDENTIFIED BUSINESS OF ARCO LAB
Source text: ID:nNSEbkyWGB
Further company coverage: SRID.NS
Strides Pharma Science Unit Proposes To Acquire 100% Stake In Amexel
March 14 (Reuters) - Strides Pharma Science Ltd SRID.NS:
STRIDES PHARMA SCIENCE LTD - UNIT PROPOSED TO ACQUIRE 100% STAKE IN AMEXEL PTE. LTD.
STRIDES PHARMA SCIENCE LTD - UNIT PROPOSES TO CREATE BUSINESS PLATFORM IN SOUTHEAST ASIA
Source text: ID:nBSE5Grkf4
Further company coverage: SRID.NS
March 14 (Reuters) - Strides Pharma Science Ltd SRID.NS:
STRIDES PHARMA SCIENCE LTD - UNIT PROPOSED TO ACQUIRE 100% STAKE IN AMEXEL PTE. LTD.
STRIDES PHARMA SCIENCE LTD - UNIT PROPOSES TO CREATE BUSINESS PLATFORM IN SOUTHEAST ASIA
Source text: ID:nBSE5Grkf4
Further company coverage: SRID.NS
Strides Pharma Science Dec-Quarter Consol Net Profit 879.5 Million Rupees
Jan 30 (Reuters) - Strides Pharma Science Ltd SRID.NS:
STRIDES PHARMA SCIENCE DEC-QUARTER CONSOL NET PROFIT 879.5 MILLION RUPEES
STRIDES PHARMA SCIENCE DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 11.54 BILLION RUPEES
Source text: ID:nBSE6pp5YM
Further company coverage: SRID.NS
Jan 30 (Reuters) - Strides Pharma Science Ltd SRID.NS:
STRIDES PHARMA SCIENCE DEC-QUARTER CONSOL NET PROFIT 879.5 MILLION RUPEES
STRIDES PHARMA SCIENCE DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 11.54 BILLION RUPEES
Source text: ID:nBSE6pp5YM
Further company coverage: SRID.NS
Strides Pharma Science Receives USFDA Approval For Acetaminophen And Ibuprofen Tablets
Jan 20 (Reuters) - Strides Pharma Science Ltd SRID.NS:
STRIDES PHARMA SCIENCE LTD - RECEIVES USFDA APPROVAL FOR ACETAMINOPHEN AND IBUPROFEN TABLETS
STRIDES PHARMA SCIENCE LTD - APPROVAL WILL ENHANCE STRIDES' OTC PRODUCT PORTFOLIO
Source text: ID:nBSEbPMJqh
Further company coverage: SRID.NS
Jan 20 (Reuters) - Strides Pharma Science Ltd SRID.NS:
STRIDES PHARMA SCIENCE LTD - RECEIVES USFDA APPROVAL FOR ACETAMINOPHEN AND IBUPROFEN TABLETS
STRIDES PHARMA SCIENCE LTD - APPROVAL WILL ENHANCE STRIDES' OTC PRODUCT PORTFOLIO
Source text: ID:nBSEbPMJqh
Further company coverage: SRID.NS
Strides Pharma Science Says Receipt Of NCLT Approval For Creation Of Onesource
Nov 19 (Reuters) - Strides Pharma Science Ltd SRID.NS:
RECEIPT OF NCLT APPROVAL FOR CREATION OF ONESOURCE
FOLLOWING APPROVAL, ONESOURCE WILL ADVANCE TOWARDS LISTING ITS SHARES
Source text: ID:nNSE69gFWY
Further company coverage: SRID.NS
Nov 19 (Reuters) - Strides Pharma Science Ltd SRID.NS:
RECEIPT OF NCLT APPROVAL FOR CREATION OF ONESOURCE
FOLLOWING APPROVAL, ONESOURCE WILL ADVANCE TOWARDS LISTING ITS SHARES
Source text: ID:nNSE69gFWY
Further company coverage: SRID.NS
Strides Pharma Science Unit Buys Remaining Stake In Strides Switzerland For CHF 1.01 Mln
Oct 25 (Reuters) - Strides Pharma Science Ltd SRID.NS:
UNIT SPG ACQUIRES REMAINING STAKE IN STRIDES SWITZERLAND FOR CHF 1.01 MILLION
Source text for Eikon: ID:nBSE3YQjWM
Further company coverage: SRID.NS
Oct 25 (Reuters) - Strides Pharma Science Ltd SRID.NS:
UNIT SPG ACQUIRES REMAINING STAKE IN STRIDES SWITZERLAND FOR CHF 1.01 MILLION
Source text for Eikon: ID:nBSE3YQjWM
Further company coverage: SRID.NS
India's Strides Pharma gains on posting Q2 profit
** Shares of Strides Pharma Science SRID.NS rise 2.5% to 1,599.5 rupees
** The pharma co posted a consolidated net profit of 932.3 mln rupees ($11 mln) vs a loss of 1.31 bln rupees a year ago
** Rev from ops rose 20% Y/Y
** More than 385,000 shares change hands, 1.1x its 30 day avg
** Stock has surged over two-fold so far this year
($1 = 84.0510 Indian rupees)
(Reporting by Ashna Teresa Britto in Bengaluru)
((AshnaTeresa.Britto@thomsonreuters.com ; ( +91 8078332441))
** Shares of Strides Pharma Science SRID.NS rise 2.5% to 1,599.5 rupees
** The pharma co posted a consolidated net profit of 932.3 mln rupees ($11 mln) vs a loss of 1.31 bln rupees a year ago
** Rev from ops rose 20% Y/Y
** More than 385,000 shares change hands, 1.1x its 30 day avg
** Stock has surged over two-fold so far this year
($1 = 84.0510 Indian rupees)
(Reporting by Ashna Teresa Britto in Bengaluru)
((AshnaTeresa.Britto@thomsonreuters.com ; ( +91 8078332441))
Strides Pharma Science Says Onesource Gets Equity Commitments Of 8.01 Bln Rupees
Oct 16 (Reuters) - Strides Pharma Science Ltd SRID.NS:
ONESOURCE RECEIVES EQUITY COMMITMENTS OF 8.01 BILLION RUPEES
COMMITMENTS FROM MARQUEE INVESTORS AT PRE-MONEY EQUITY VALUATION OF $1.65 BILLION
Source text for Eikon: ID:nBSE7MJ6X7
Further company coverage: SRID.NS
Oct 16 (Reuters) - Strides Pharma Science Ltd SRID.NS:
ONESOURCE RECEIVES EQUITY COMMITMENTS OF 8.01 BILLION RUPEES
COMMITMENTS FROM MARQUEE INVESTORS AT PRE-MONEY EQUITY VALUATION OF $1.65 BILLION
Source text for Eikon: ID:nBSE7MJ6X7
Further company coverage: SRID.NS
Strides Pharma Science Says RBI Levies Compounding Amount Of 15.1 Million Rupees On Co
Sept 17 (Reuters) - Strides Pharma Science Ltd SRID.NS:
RBI HAS LEVIED COMPOUNDING AMOUNT OF 15.1 MILLION RUPEES ON COMPANY
ORDER IN MATTER OF GRANT OF STOCK OPTONS TO NONRESIDENT EMPLOYEE
Further company coverage: SRID.NS
Sept 17 (Reuters) - Strides Pharma Science Ltd SRID.NS:
RBI HAS LEVIED COMPOUNDING AMOUNT OF 15.1 MILLION RUPEES ON COMPANY
ORDER IN MATTER OF GRANT OF STOCK OPTONS TO NONRESIDENT EMPLOYEE
Further company coverage: SRID.NS
Strides Pharma Science Gets USFDA Approval For Fluoxetine Tabs 60 Mg
Sept 16 (Reuters) - Strides Pharma Science Ltd SRID.NS:
STRIDES PHARMA SCIENCE LTD - RECEIVES USFDA APPROVAL FOR FLUOXETINE TABS 60 MG
Source text for Eikon: ID:nBSEf6hKM
Further company coverage: SRID.NS
Sept 16 (Reuters) - Strides Pharma Science Ltd SRID.NS:
STRIDES PHARMA SCIENCE LTD - RECEIVES USFDA APPROVAL FOR FLUOXETINE TABS 60 MG
Source text for Eikon: ID:nBSEf6hKM
Further company coverage: SRID.NS
India's Strides Pharma rises on US FDA nod for drug to treat asthma, lung diseases
** Shares of Strides Pharma Science SRID.NS rise 2.4% to 1,376.8 rupees
** The pharma products maker's unit gets approval from U.S. Food and Drug Administration for generic version of a drug used to treat chronic asthma and lung diseases like emphysema and bronchitis
** The drug - Theophylline extended-release tablet - has a market size of $11.5 million, as per pharma analytics and research firm IQVIA
** SRID shares up 113% in 2024 so far, helped by steady earnings and U.S. drug regulator approvals for several key products
(Reporting by Bharath Rajeswaran in Bengaluru)
((bharath.rajeswaran@thomsonreuters.com; +91 9769003463;))
** Shares of Strides Pharma Science SRID.NS rise 2.4% to 1,376.8 rupees
** The pharma products maker's unit gets approval from U.S. Food and Drug Administration for generic version of a drug used to treat chronic asthma and lung diseases like emphysema and bronchitis
** The drug - Theophylline extended-release tablet - has a market size of $11.5 million, as per pharma analytics and research firm IQVIA
** SRID shares up 113% in 2024 so far, helped by steady earnings and U.S. drug regulator approvals for several key products
(Reporting by Bharath Rajeswaran in Bengaluru)
((bharath.rajeswaran@thomsonreuters.com; +91 9769003463;))
Strides Pharma Science June-Quarter Consol Net Profit 702 Mln Rupees
July 29 (Reuters) - Strides Pharma Science Ltd SRID.NS:
INDIA’S STRIDES PHARMA SCIENCE JUNE-QUARTER CONSOL NET PROFIT 702 MILLION
STRIDES PHARMA SCIENCE JUNE-QUARTER CONSOL REVENUE FROM CONTINUING OPERATIONS 10.88 BILLION RUPEES
Source text for Eikon: [ID:]
Further company coverage: SRID.NS
July 29 (Reuters) - Strides Pharma Science Ltd SRID.NS:
INDIA’S STRIDES PHARMA SCIENCE JUNE-QUARTER CONSOL NET PROFIT 702 MILLION
STRIDES PHARMA SCIENCE JUNE-QUARTER CONSOL REVENUE FROM CONTINUING OPERATIONS 10.88 BILLION RUPEES
Source text for Eikon: [ID:]
Further company coverage: SRID.NS
India's Strides Pharma jumps after reporting Q4 profit
** Shares of Strides Pharma Science SRID.NS up 7.8% at 911.75 rupees after rising as much as 8.7% earlier
** Pharmaceutical co reports Q4 consolidated net profit at 181.8 mln rupees ($2.2 mln) vs loss of 95.4 mln rupees yr ago
** Rev from ops rose 9.9% Y/Y
** Stock is witnessing its most active trading session since Feb. 14, with more than 1.6 mln shares changing hands, 5.8x of 30-day avg
** Co sees continuing business revenue to grow at 12-15% Y/Y for FY25
** Says its U.S. business revenue to be in $285 mln-$300 mln range for FY25
** Stock rose ~21% in March quarter, its fourth straight quarterly rise
($1 = 83.2502 Indian rupees)
(Reporting by Ashish Chandra in Bengaluru)
((ashish.chandra@thomsonreuters.com (+91 7982114624))
** Shares of Strides Pharma Science SRID.NS up 7.8% at 911.75 rupees after rising as much as 8.7% earlier
** Pharmaceutical co reports Q4 consolidated net profit at 181.8 mln rupees ($2.2 mln) vs loss of 95.4 mln rupees yr ago
** Rev from ops rose 9.9% Y/Y
** Stock is witnessing its most active trading session since Feb. 14, with more than 1.6 mln shares changing hands, 5.8x of 30-day avg
** Co sees continuing business revenue to grow at 12-15% Y/Y for FY25
** Says its U.S. business revenue to be in $285 mln-$300 mln range for FY25
** Stock rose ~21% in March quarter, its fourth straight quarterly rise
($1 = 83.2502 Indian rupees)
(Reporting by Ashish Chandra in Bengaluru)
((ashish.chandra@thomsonreuters.com (+91 7982114624))
India's Strides Pharma up after US FDA nod for kidney disease drug
** Shares of Strides Pharma Science SRID.NS are up around 2%
** SRID gets US FDA approval for Sevelamer Carbonate tablets, used to manage elevated phosphate levels in blood of patients with chronic kidney disease
** Stock is set to post its worst week since early Jan, down 4% for the week
** SRID up 31% YTD vs a 11% rise in Nifty Pharma Index .NIPHARM
(Reporting by Nishit Navin)
** Shares of Strides Pharma Science SRID.NS are up around 2%
** SRID gets US FDA approval for Sevelamer Carbonate tablets, used to manage elevated phosphate levels in blood of patients with chronic kidney disease
** Stock is set to post its worst week since early Jan, down 4% for the week
** SRID up 31% YTD vs a 11% rise in Nifty Pharma Index .NIPHARM
(Reporting by Nishit Navin)
Strides Pharma Science Says Unit Receives USFDA Approval For Fluoxetine Tabs
April 9 (Reuters) - Strides Pharma Science Ltd SRID.NS:
STRIDES RECEIVES USFDA APPROVAL FOR FLUOXETINE TABS 10 MG AND 20 MG
Source text for Eikon: ID:nBSE6GNL4V
Further company coverage: SRID.NS
April 9 (Reuters) - Strides Pharma Science Ltd SRID.NS:
STRIDES RECEIVES USFDA APPROVAL FOR FLUOXETINE TABS 10 MG AND 20 MG
Source text for Eikon: ID:nBSE6GNL4V
Further company coverage: SRID.NS
Strides Pharma Science Proposes To Consolidate Group's South African Business Under Trinity Pharma (Proprietary), South Africa
March 29 (Reuters) - Strides Pharma Science Ltd SRID.NS:
STRIDES PHARMA SCIENCE LTD - PROPOSES TO CONSOLIDATE GROUP'S SOUTH AFRICAN BUSINESS UNDER TRINITY PHARMA (PROPRIETARY) LIMITED, SOUTH AFRICA
Source text for Eikon: ID:nBSE15mLyg
Further company coverage: SRID.NS
March 29 (Reuters) - Strides Pharma Science Ltd SRID.NS:
STRIDES PHARMA SCIENCE LTD - PROPOSES TO CONSOLIDATE GROUP'S SOUTH AFRICAN BUSINESS UNDER TRINITY PHARMA (PROPRIETARY) LIMITED, SOUTH AFRICA
Source text for Eikon: ID:nBSE15mLyg
Further company coverage: SRID.NS
Strides Pharma Science Says Insolvency Resolution Against Strides Alathur Stands Stayed
March 28 (Reuters) - Strides Pharma Science Ltd SRID.NS:
CORPORATE INSOLVENCY RESOLUTION PROCESS AGAINST STRIDES ALATHUR STANDS STAYED BY APPELLATE TRIBUNAL
Source text for Eikon: ID:nBSE7qH1Gm
Further company coverage: SRID.NS
March 28 (Reuters) - Strides Pharma Science Ltd SRID.NS:
CORPORATE INSOLVENCY RESOLUTION PROCESS AGAINST STRIDES ALATHUR STANDS STAYED BY APPELLATE TRIBUNAL
Source text for Eikon: ID:nBSE7qH1Gm
Further company coverage: SRID.NS
India's Strides Pharma rises on USFDA nod for Gabapentin tablets
** Shares of Strides Pharma Science SRID.NS up 2.3%
** Stock roses as much as 4.8% to day's high of 834.6 rupees
** Pharmaceutical co's unit received U.S. FDA approval for Gabapentin Tablets USP, 600 mg and 800 mg
** It is a commonly used medication for the treatment of neuropathic pain caused by diabetic neuropathy, postherpetic neuralgia, and central pain
** The product is bioequivalent to the reference-listed drug Neurontin Tablets, 600 mg and 800 mg, from Viatris Specialty LLC, co added
** The drug will be manufactured at Strides' Puducherry facility
** Stock is up 25.4% so far this year; after rising 85.6% in 2023
(Reporting by Navamya Ganesh Acharya in Bengaluru)
((Navamya.GaneshAcharya@thomsonreuters.com; +91 8805175330 ;))
** Shares of Strides Pharma Science SRID.NS up 2.3%
** Stock roses as much as 4.8% to day's high of 834.6 rupees
** Pharmaceutical co's unit received U.S. FDA approval for Gabapentin Tablets USP, 600 mg and 800 mg
** It is a commonly used medication for the treatment of neuropathic pain caused by diabetic neuropathy, postherpetic neuralgia, and central pain
** The product is bioequivalent to the reference-listed drug Neurontin Tablets, 600 mg and 800 mg, from Viatris Specialty LLC, co added
** The drug will be manufactured at Strides' Puducherry facility
** Stock is up 25.4% so far this year; after rising 85.6% in 2023
(Reporting by Navamya Ganesh Acharya in Bengaluru)
((Navamya.GaneshAcharya@thomsonreuters.com; +91 8805175330 ;))
India's Strides Pharma gains on posting Q3 profit
** Shares of Strides Pharma Science SRID.NS up 3.4%, easing from a jump of as much as 6.2% after Q3 results
** The pharma company reported a Q3 profit vs a year-ago loss, aided by high revenue from U.S. ops
** Stock has been trading above its 100-, 200- day simple moving average since April 2023
** Stock now up just over 8% YTD; its soared ~86% in 2023 after two years of losses
(Reporting by Manvi Pant in Bengaluru)
((Manvi.Pant@thomsonreuters.com; +918447554364;))
** Shares of Strides Pharma Science SRID.NS up 3.4%, easing from a jump of as much as 6.2% after Q3 results
** The pharma company reported a Q3 profit vs a year-ago loss, aided by high revenue from U.S. ops
** Stock has been trading above its 100-, 200- day simple moving average since April 2023
** Stock now up just over 8% YTD; its soared ~86% in 2023 after two years of losses
(Reporting by Manvi Pant in Bengaluru)
((Manvi.Pant@thomsonreuters.com; +918447554364;))
Strides Pharma Science Unit To Divest 100% Stake In Eris Pharma GmbH, Germany
Jan 11 (Reuters) - Strides Pharma Science Ltd SRID.NS:
UNIT ENTERED INTO A SHARE PURCHASE AGREEMENT FOR DIVESTMENT OF 100% SHAREHOLDING IN ERIS PHARMA GMBH, GERMANY
DEAL FOR EURO 200,000
Source text for Eikon: ID:nBSE3vsMl7
Further company coverage: SRID.NS
Jan 11 (Reuters) - Strides Pharma Science Ltd SRID.NS:
UNIT ENTERED INTO A SHARE PURCHASE AGREEMENT FOR DIVESTMENT OF 100% SHAREHOLDING IN ERIS PHARMA GMBH, GERMANY
DEAL FOR EURO 200,000
Source text for Eikon: ID:nBSE3vsMl7
Further company coverage: SRID.NS
Strides Pharma Science Unit Acquires Additional Stake In Neviton Softech
Jan 5 (Reuters) - Strides Pharma Science Ltd SRID.NS:
STRIDES PHARMA SCIENCE LTD - UNIT ACQUIRED ADDITIONAL STAKE IN NEVITON SOFTECH
Source text for Eikon: ID:nBSEb0zDJ7
Further company coverage: SRID.NS
Jan 5 (Reuters) - Strides Pharma Science Ltd SRID.NS:
STRIDES PHARMA SCIENCE LTD - UNIT ACQUIRED ADDITIONAL STAKE IN NEVITON SOFTECH
Source text for Eikon: ID:nBSEb0zDJ7
Further company coverage: SRID.NS
Strides Pharma Science Says Unit Availed Credit Facility From A Division Of Investec Bank, South Africa
Dec 21 (Reuters) - Strides Pharma Science Ltd SRID.NS:
UNIT AVAILED CREDIT FACILITY FROM A DIVISION OF INVESTEC BANK, SOUTH AFRICA
UNIT AVAILED CREDIT FACILITY FOR THEIR WORKING CAPITAL REQUIREMENTS
Further company coverage: SRID.NS
Dec 21 (Reuters) - Strides Pharma Science Ltd SRID.NS:
UNIT AVAILED CREDIT FACILITY FROM A DIVISION OF INVESTEC BANK, SOUTH AFRICA
UNIT AVAILED CREDIT FACILITY FOR THEIR WORKING CAPITAL REQUIREMENTS
Further company coverage: SRID.NS
Strides Pharma Science Launches Icosapent Ethyl Acid Soft Gel Capsules In Partnership With Amneal
Dec 1 (Reuters) - Strides Pharma Science Ltd SRID.NS:
LAUNCHES ICOSAPENT ETHYL ACID SOFT GEL CAPSULES IN PARTNERSHIP WITH AMNEAL
Source text for Eikon: [ID:]
Further company coverage: SRID.NS
Dec 1 (Reuters) - Strides Pharma Science Ltd SRID.NS:
LAUNCHES ICOSAPENT ETHYL ACID SOFT GEL CAPSULES IN PARTNERSHIP WITH AMNEAL
Source text for Eikon: [ID:]
Further company coverage: SRID.NS
Events:
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
More Small Cap Ideas
See similar 'Small' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Strides Pharma Scien do?
Strides Pharma Science Limited is a global pharmaceutical company established in 1990, with headquarters in Bangalore, India. It operates in Regulated Markets and Emerging Markets, with a strong R&D facility and presence in 100 countries.
Who are the competitors of Strides Pharma Scien?
Strides Pharma Scien major competitors are Viyash Scientific, Procter&Gamble Healt, Marksans Pharma, Sanofi India, Caplin Point Lab, FDC, Alembic Pharma. Market Cap of Strides Pharma Scien is ₹8,938 Crs. While the median market cap of its peers are ₹7,919 Crs.
Is Strides Pharma Scien financially stable compared to its competitors?
Strides Pharma Scien seems to be less financially stable compared to its competitors. Altman Z score of Strides Pharma Scien is 3.46 and is ranked 7 out of its 8 competitors.
Does Strides Pharma Scien pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Strides Pharma Scien latest dividend payout ratio is 1.03% and 3yr average dividend payout ratio is 1.03%
How has Strides Pharma Scien allocated its funds?
Companies resources are allocated to majorly unproductive assets like Inventory
How strong is Strides Pharma Scien balance sheet?
Balance sheet of Strides Pharma Scien is strong. But short term working capital might become an issue for this company.
Is the profitablity of Strides Pharma Scien improving?
The profit is oscillating. The profit of Strides Pharma Scien is ₹529 Crs for TTM, ₹3,593 Crs for Mar 2025 and -₹70.61 Crs for Mar 2024.
Is the debt of Strides Pharma Scien increasing or decreasing?
Yes, The net debt of Strides Pharma Scien is increasing. Latest net debt of Strides Pharma Scien is ₹1,606 Crs as of Sep-25. This is greater than Mar-25 when it was ₹1,538 Crs.
Is Strides Pharma Scien stock expensive?
Strides Pharma Scien is expensive when considering the PE ratio, however latest EV/EBIDTA is < 3 yr avg EV/EBIDTA. Latest PE of Strides Pharma Scien is 17.48, while 3 year average PE is 7.0. Also latest EV/EBITDA of Strides Pharma Scien is 11.67 while 3yr average is 20.89.
Has the share price of Strides Pharma Scien grown faster than its competition?
Strides Pharma Scien has given lower returns compared to its competitors. Strides Pharma Scien has grown at ~-2.13% over the last 10yrs while peers have grown at a median rate of 7.02%
Is the promoter bullish about Strides Pharma Scien?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Strides Pharma Scien is 27.86% and last quarter promoter holding is 27.86%.
Are mutual funds buying/selling Strides Pharma Scien?
The mutual fund holding of Strides Pharma Scien is increasing. The current mutual fund holding in Strides Pharma Scien is 8.59% while previous quarter holding is 8.48%.